Hamlet BioPharma AB publ (XSAT:HAMLET B) Notes Receivable: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:HAMLET B Hamlet BioPharma AB publ XSAT:HAMLET B
31 GF Score
Price kr6.67
! 2 Warning Signs
View Full Analysis

What is Hamlet BioPharma AB publ Notes Receivable?

Hamlet BioPharma AB publ XSAT:HAMLET B -1.91% 31 Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus rates XSAT:HAMLET B with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Hamlet BioPharma AB publ's Notes Receivable for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Hamlet BioPharma AB publ Notes Receivable Related Terms

Hamlet BioPharma AB publ Notes Receivable Historical Data

* Premium members only.

The historical data trend for Hamlet BioPharma AB publ's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hamlet BioPharma AB publ Notes Receivable Chart

Hamlet BioPharma AB publ Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hamlet BioPharma AB publ Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSAT:HAMLET B
31GF Score
Hamlet BioPharma AB publ XSAT:HAMLET B
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hamlet BioPharma AB publ Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of kr0.00 Mil mean?
Hamlet BioPharma AB publ (XSAT:HAMLET B) has a Notes Receivable of kr0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Hamlet BioPharma AB publ and its competitors.
Is Hamlet BioPharma AB publ's Notes Receivable too high?
Hamlet BioPharma AB publ's current Notes Receivable is kr0.00 Mil. Overall, Hamlet BioPharma AB publ has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hamlet BioPharma AB publ's Notes Receivable compare to VRTX and REGN?
Hamlet BioPharma AB publ's Notes Receivable of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Hamlet BioPharma AB publ and its competitors. Hamlet BioPharma AB publ's current Notes Receivable is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamlet BioPharma AB publ stock overvalued right now?
Hamlet BioPharma AB publ (XSAT:HAMLET B) has a current Notes Receivable of kr0.00 Mil. The current Notes Receivable is kr0.00 Mil. Hamlet BioPharma AB publ's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Hamlet BioPharma AB publ (XSAT:HAMLET B), the current Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hamlet BioPharma AB publ Business Description

Other Exchanges 7ZT:Germany
Address Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
31GF Score

Get the complete analysis for XSAT:HAMLET B

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.67
Price